Form 4: Gossamer Bio Executive Acquires 572,000 Stock Options

Robert Paul Smith JR, Chief Commercial Officer of Gossamer Bio, Inc., acquired 572,000 stock options on March 4, 2025, at an exercise price of $1.13.

Summary

• Robert Paul Smith JR, the Chief Commercial Officer of Gossamer Bio, Inc., filed a Form 4 with the SEC.
• The filing reports the acquisition of 572,000 stock options on March 4, 2025.
• The exercise price of these options is $1.13 per share.
• The options vest over time, with 25% vesting on March 4, 2026, and the remainder vesting monthly thereafter, contingent upon continuous service.

Sentiment

Score: 6

Explanation: Neutral sentiment as it's a standard executive compensation disclosure. The acquisition of stock options can be seen as a positive sign of confidence, but it's not a major event.

Positives

• The acquisition of stock options by a key executive could be seen as a positive sign, indicating confidence in the company's future performance.

Industry Context

This is a standard SEC filing related to executive compensation. Stock options are a common form of compensation in the biotech industry.

Comparison to Industry Standards

• Stock option grants are a typical component of executive compensation packages in the biotechnology industry.
• The vesting schedule of 25% after one year followed by monthly vesting is a fairly standard arrangement to incentivize long-term commitment.
• Comparing the size of the grant to similar companies and executive roles would require further analysis of Gossamer Bio's compensation strategy.

Stakeholder Impact

• The granting of stock options could potentially align the executive's interests with those of the shareholders.

Key Dates